Alcresta Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Alcresta Therapeutics, Inc.
With $845m raised to date, ElevateBio will keep building its cell and gene therapy manufacturing capabilities and continue creating new companies and partnerships, but with a global focus.
Derived from Strategic Transactions, Informa's premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced June through July 2016.
In this month's issue of Start-Up, we profile Alcresta Pharmaceuticals, Gordian Surgical, International Biomedical Devices, NaviGate Cardiac Structures, ObsEva and SweetBio.
Alcresta Pharmaceuticals Inc. aims to combat malabsorption, with an initial focus on enzyme deficiencies, for people with gastrointestinal disorders and rare diseases. It is developing a pipeline of point-of-care nutritional products tailored to maximize the absorption of calories or specific nutrients, based on cartridges enclosing enzymes immobilized onto polymer beads.
- Large Molecule
- Other Names / Subsidiaries
- Alcresta Pharmaceuticals, Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.